Leukocytes

OrganaBio Announces the Addition of Adult Peripheral Blood-Derived Leukopaks to its Portfolio of Products for Cell Therapy Development

Retrieved on: 
Tuesday, June 1, 2021
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Branches of biology, Clinical medicine, Medicine, Hematology, Cell biology, Transfusion medicine, Stem cells, Leukocytes, Peripheral blood mononuclear cell, Leukapheresis, Cell therapy, Apheresis

OrganaBio, LLC (OrganaBio) announces the launch of adult peripheral blood-derived products, including vialed peripheral blood mononuclear cells (PBMCs) and whole leukopaks (LeukoPAC).

Key Points: 
  • OrganaBio, LLC (OrganaBio) announces the launch of adult peripheral blood-derived products, including vialed peripheral blood mononuclear cells (PBMCs) and whole leukopaks (LeukoPAC).
  • (Photo: OrganaBio)
    The new leukapheresis-derived products portfolio is obtained from consented, compensated donors under IRB-approved protocols.
  • The addition of adult blood-derived products to OrganaBios portfolio of perinatal tissue- and blood-derived cell products and media systems furthers OrganaBios mission to provide critical cellular raw materials that are not readily accessible to cell therapy developers.
  • OrganaBio manufactures off-the-shelf research grade products for allogeneic cell therapy development and is building cGMP manufacturing capabilities, with a forecasted launch in Q3 2021.

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

Retrieved on: 
Tuesday, June 1, 2021
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Medicine, Cytokines, Growth factors, Blood, Leukocytes, Neutropenia, Spectrum Pharmaceuticals, Granulocyte colony-stimulating factor, Medication, Bone marrow suppression, ROLONTIS, Spectrum Pharmaceuticals, Inc., ROLONTIS, SPECTRUM PHARMACEUTICALS, INC.

I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.

Key Points: 
  • I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
  • ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

Retrieved on: 
Thursday, April 29, 2021
Research, Infectious diseases, Public relations, Investor relations, Clinical trials, Communications, AIDS, General Health, Health, Science, Other Science, Branches of biology, Medical specialties, Leukocytes, Human physiology, Immune system, Immunology, T cells, Lymphocytes, Natural killer cell, Agranulocyte, HIV, Peripheral blood mononuclear cell

Researchers will compare levels of HIV RNA and DNA in lymph node samples pre- and post-treatment and evaluate the therapy\xe2\x80\x99s effects on CD8+ T and natural killer (NK) immune cells.

Key Points: 
  • Researchers will compare levels of HIV RNA and DNA in lymph node samples pre- and post-treatment and evaluate the therapy\xe2\x80\x99s effects on CD8+ T and natural killer (NK) immune cells.
  • There was also evidence that Anktiva activated viral transcription and reduced the viral reservoir in peripheral blood mononuclear cells.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005421/en/\n'

USPTO Issues New Patents for Cell Source's Veto Cell Technology

Retrieved on: 
Friday, March 19, 2021
Branches of biology, Biology, Clinical medicine, Biotechnology, Stem cells, Cancer immunotherapy, Leukocytes, Veto cells, Hematopoietic stem cell transplantation, Immunotherapy, Cancer

NEW YORK, March 19, 2021 /PRNewswire/ --Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g.

Key Points: 
  • NEW YORK, March 19, 2021 /PRNewswire/ --Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g.
  • Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology.
  • Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist.
  • "These issued patents reiterate the versatility of Veto Cells as a powerful, multi-faceted immunotherapy platform technology," said Dennis Brown, Chairman of Cell Source.

Insights on the Neutropenia Treatment Global Market to 2026 - Featuring Amgen, Novartis & Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, September 25, 2020
Biotechnology, Pharmaceutical, Health, Anatomy, Blood disorders, Medical specialties, Blood, Leukocytes, Neutropenia, Organ systems

The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global neutropenia treatment market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period.
  • One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules.
  • Currently, there is a high demand for cost-effective drugs for treatment in the neutropenia treatment market.

Global Neutropenia Treatment Market (2020 to 2026) - by Distribution Channel, Treatment, Region, Industry Analysis and Forecast

Retrieved on: 
Friday, September 25, 2020
Anatomy, Blood disorders, Medical specialties, Blood, Leukocytes, Neutropenia, Organ systems

DUBLIN, Sept. 25, 2020 /PRNewswire/ -- The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 25, 2020 /PRNewswire/ -- The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global neutropenia treatment market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period.
  • One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules.
  • Currently, there is a high demand for cost-effective drugs for treatment in the neutropenia treatment market.

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Retrieved on: 
Saturday, September 19, 2020
Autoimmune diseases, Blood disorders, Anatomy, Blood, Leukocytes, Neutropenia, Medical specialties, Organ systems, RTT

Trodelvy continued to demonstrate a tolerable and predictable safety profile consistent with previous observations in mUC and other tumor types.

Key Points: 
  • Trodelvy continued to demonstrate a tolerable and predictable safety profile consistent with previous observations in mUC and other tumor types.
  • Treatment-related Grade 3 and 4 adverse events were mostly hematologic and gastrointestinal related, including neutropenia (34%) and diarrhea (10%).
  • Seven patients (6%) discontinued treatment due to adverse events, three of whom due to neutropenia or its complications.
  • There were no grade 2 or above events of neuropathy or rash, and no cases of interstitial lung disease reported.

Worldwide Neutropenia Treatment Industry to 2027 - Robust Drug Pipeline for Neutropenia Treatment Presents Opportunities

Retrieved on: 
Wednesday, July 22, 2020
Anatomy, Blood, Leukocytes, Neutropenia, Medical specialties, Organ systems

DUBLIN, July 22, 2020 /PRNewswire/ -- The "Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 22, 2020 /PRNewswire/ -- The "Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.
  • However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period.
  • Key Findings of the Study:
    Based on treatment, the colony-stimulating factors segment accounted for a $10, 211.5 in the global neutropenia market in 2019.

Global Neutropenia Treatment Market (2020 to 2027) - by Treatment, and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Monday, July 20, 2020
Health, Pharmaceutical, Medical specialties, Anatomy, Blood disorders, Organ systems, Blood, Leukocytes, Neutropenia

The "Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.
  • The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
  • Key Findings of the Study:
    Based on treatment, the colony-stimulating factors segment accounted for a $10, 211.5 in the global neutropenia market in 2019.

Vor Biopharma Appoints Daniella Beckman to its Board of Directors

Retrieved on: 
Thursday, July 16, 2020
Biotechnology, Health, Stem cells, Pharmaceutical, Oncology, Branches of biology, Stem cells, Hematopoietic stem cell, Leukocytes, Vor Biopharma, VOR33

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors.

Key Points: 
  • Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors.
  • Ms. Beckman joins Vor with deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career.
  • In addition to Vor, Ms. Beckman also serves on the Board of Directors of Translate Bio as Chair of the Audit and the Nomination and Governance Committees.
  • Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies.